About: Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody
Creator	Wang, Lin-Fa Crameri, Gary Middleton, Deborah Zhu, Zhongyu Feng, Yang Bossart, Katharine Broder, Christopher Dimitrov, Dimiter Mceachern, Jennifer Dimitrov, Antony Bishop, Kimberly
Source	Medline; PMC
abstract	We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) and Hendra virus (HeV) by panning a large nonimmune antibody library against a soluble form of the HeV attachment-envelope glycoprotein G (sG(HeV)). One of these antibodies, m102, which exhibited the highest level of cross-reactive neutralization of both NiV and HeV G, was affinity maturated by light-chain shuffling combined with random mutagenesis of its heavy-chain variable domain and panning against sG(HeV). One of the selected antibody Fab clones, m102.4, had affinity of binding to sG(HeV) that was equal to or higher than that of the other Fabs; it was converted to IgG1 and tested against infectious NiV and HeV. It exhibited exceptionally potent and cross-reactive inhibitory activity with 50% inhibitory concentrations below 0.04 and 0.6 μg/mL, respectively. The virus-neutralizing activity correlated with the binding affinity of the antibody to sG(HeV) and sG(NiV). m102.4 bound a soluble form of NiV G (sG(NiV)) better than it bound sG(HeV), and it neutralized NiV better than HeV, despite being originally selected against sG(HeV). These results suggest that m102.4 has potential as a therapeutic agent for the treatment of diseases caused by henipaviruses. It could be also used for prophylaxis and diagnosis, and as a research reagent
has issue date	2008-03-15(xsd:dateTime)
bibo:doi	10.1086/528801
bibo:pmid	18271743
has license	no-cc
sha1sum (hex)	a3e7de27fa4bd4db98f662490e380195609d16bf
schema:url	https://doi.org/10.1086/528801
resource representing a document's title	Exceptionally Potent Cross-Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody
has PubMed Central identifier	PMC7199872
has PubMed identifier	18271743
schema:publication	J Infect Dis
resource representing a document's body	covid:a3e7de27fa4bd4db98f662490e380195609d16bf#body_text
is schema:about of	named entity 'therapeutic' named entity 'monoclonal antibodies' named entity 'clones' named entity 'affinity' named entity 'm102' named entity 'Human' named entity 'AFFINITY' named entity 'ATTACHMENT' named entity 'HUMAN' named entity 'CLONES' named entity 'NIPAH VIRUS' named entity 'light-chain' named entity 'diagnosis' named entity 'NiV' named entity 'potential' named entity 'reagent' named entity 'bound' named entity 'prophylaxis' named entity 'NiV' named entity 'HeV' named entity 'reagent' named entity 'NiV' named entity 'cross-reactive' named entity 'virus' named entity 'antigen' named entity 'reagent' named entity 'antigens' named entity 'Fred Hutchinson Cancer Research Center' named entity 'Queensland' named entity 'ketamine' named entity 'variable domain' named entity 'plasma half-life' named entity 'jugular vein' named entity 'm101' named entity 'small molecule' named entity 'NiV' named entity 'antibodies' named entity '37°C' named entity 'serum samples' named entity 'NiV' named entity 'Vero cell' named entity 'case fatality rates' named entity 'animal models' named entity 'plasma' named entity 'Vero cells' named entity 'microscopy' named entity 'Cell fusion' named entity 'serum' named entity 'cell cultures' named entity 'biological activity' named entity 'axillary vein' named entity 'peroxidase' named entity 'fermentation' named entity 'peninsular Malaysia' named entity 'vaccine' named entity 'IgG1' named entity 'henipavirus' named entity 'cross-reactivity' named entity 'prophylaxis' named entity 'm101' named entity 'antibody' named entity 'protein' named entity 'Ferret' named entity 'ephrin-B3' named entity 'virus' named entity 'Novartis' named entity 'cell line' named entity 'NiV' named entity 'SARS coronavirus' named entity 'antiviral' named entity 'Stratagene'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software